Download PDF
Int J Angiol 2023; 32(04): 238-242
DOI: 10.1055/s-0041-1731088
Original Article

Association and Implications of Blood and Plaque n-3 Polyunsaturated Fatty Acid Composition in Patients Treated with Oral Eicosapentaenoic Acid before Carotid Endarterectomy

Tatsuya Ishikawa 
1   Department of Neurosurgery, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan
,
Koji Yamaguchi
1   Department of Neurosurgery, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan
,
Takayuki Funatsu
1   Department of Neurosurgery, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan
,
Yoshikazu Okada
1   Department of Neurosurgery, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan
,
Takakazu Kawamata
1   Department of Neurosurgery, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Long-chain n-3 polyunsaturated fatty acids (PUFA), especially eicosapentaenoic acid (EPA), have been shown to prevent atherosclerosis-related cardiovascular disease, including stroke. Recently, the ratio of serum EPA to arachidonic acid (AA; EPA/AA ratio) has been reported to be a biomarker to prevent cardiovascular disease. In this study, we evaluate whether the serum EPA/AA ratio would be a useful biomarker for determining the efficacy of orally administered EPA in preventing stroke by investigating tissue and serum EPA/AA ratios, serum inflammatory markers, and carotid artery intimamedia thickness (IMT). Patients with dyslipidemia, as the primary illness scheduled for carotid endarterectomy (CEA), were included and randomly assigned to the EPA group (EPA: 1,800 mg/day plus statin; 10 patients) or non-EPA group (statin only; 15 patients). PUFA fraction was evaluated in the tissue (post-CEA) and serum (pre-CEA and 6 months thereafter). As for the tissue PUFA fraction in the plaque, the EPA group had a significantly higher EPA/AA ratio (EPA group, 0.46; non-EPA group, 0.28; p = 0.01). At 6 months postoperatively, the EPA group had a significantly higher serum EPA/AA ratio (baseline, 0.83; follow-up, 1.60; p = 0.05). No significant differences were found for inflammatory markers and IMT. Both serum and tissue EPA/AA ratios were higher in patients treated with oral EPA. Serum EPA/AA ratio might be a useful biomarker for the efficacy of orally administered EPA.

Keywords

eicosapentaenoic acid - carotid endarterectomy - fatty acid - eicosapentaenoic acid/arachidonic acid ratio - atherosclerosis - biomarker - carotid artery stenosis

Statement of Ethics

The Ethics Committee of Tokyo Women's Medical University approved the present study (no.: 130916). All patients provided written informed consent.




Publication History

Article published online:
25 August 2021

© 2021. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Iso H, Kobayashi M, Ishihara J. et al; JPHC Study Group. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006; 113 (02) 195-202
    CrossrefPubMedGoogle Scholar
  • 2 Yokoyama M, Origasa H, Matsuzaki M. et al; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369 (9567): 1090-1098
    CrossrefPubMedGoogle Scholar
  • 3 Tanaka K, Ishikawa Y, Yokoyama M. et al; JELIS Investigators, Japan. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 2008; 39 (07) 2052-2058
    CrossrefPubMedGoogle Scholar
  • 4 Cawood AL, Ding R, Napper FL. et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 2010; 212 (01) 252-259
    CrossrefPubMedGoogle Scholar
  • 5 Nakagawa I, Park HS, Yokoyama S. et al. Pretreatment with and ongoing use of omega-3 fatty acid ethyl esters reduce the slow-flow phenomenon and prevent in-stent restenosis in patients undergoing carotid artery stenting. J Vasc Surg 2017; 66 (01) 122-129
    CrossrefPubMedGoogle Scholar
  • 6 Nishio R, Shinke T, Otake H. et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis 2014; 234 (01) 114-119
    CrossrefPubMedGoogle Scholar
  • 7 Takada K, Ishikawa S, Yokoyama N, Hosogoe N, Isshiki T. Effects of eicosapentaenoic acid on platelet function in patients taking long-term aspirin following coronary stent implantation. Int Heart J 2014; 55 (03) 228-233
    CrossrefPubMedGoogle Scholar
  • 8 Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease?. Prev Med 2004; 39 (01) 212-220
    CrossrefPubMedGoogle Scholar
  • 9 Ohnishi H, Saito Y. Eicosapentaenoic acid (EPA) reduces cardiovascular events: relationship with the EPA/arachidonic acid ratio. J Atheroscler Thromb 2013; 20 (12) 861-877
    CrossrefPubMedGoogle Scholar
  • 10 Umemoto N, Ishii H, Kamoi D. et al. Reverse association of omega-3/omega-6 polyunsaturated fatty acids ratios with carotid atherosclerosis in patients on hemodialysis. Atherosclerosis 2016; 249: 65-69
    CrossrefPubMedGoogle Scholar
  • 11 Satoh N, Shimatsu A, Kotani K. et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 2007; 30 (01) 144-146
    CrossrefPubMedGoogle Scholar
  • 12 Ishida T, Naoe S, Nakakuki M, Kawano H, Imada K. Eicosapentaenoic acid prevents saturated fatty acid-induced vascular endothelial dysfunction: involvement of long-chain Acyl-CoA synthetase. J Atheroscler Thromb 2015; 22 (11) 1172-1185
    CrossrefPubMedGoogle Scholar
  • 13 Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis 2015; 242 (01) 357-366
    CrossrefPubMedGoogle Scholar
  • 14 Yusof HM, Cawood AL, Ding R. et al. Limited impact of 2  g/day omega-3 fatty acid ethyl esters (Omacor) on plasma lipids and inflammatory markers in patients awaiting carotid endarterectomy. Mar Drugs 2013; 11 (09) 3569-3581
    CrossrefPubMedGoogle Scholar
  • 15 Cannon CP, Braunwald E, McCabe CH. et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350 (15) 1495-1504
    CrossrefPubMedGoogle Scholar
  • 16 Savchenko A, Imamura M, Ohashi R. et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008; 215 (01) 48-55
    CrossrefPubMedGoogle Scholar
  • 17 Thies F, Garry JM, Yaqoob P. et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003; 361 (9356): 477-485
    CrossrefPubMedGoogle Scholar
  • 18 Yanagisawa N, Shimada K, Miyazaki T. et al. Polyunsaturated fatty acid levels of serum and red blood cells in apparently healthy Japanese subjects living in an urban area. J Atheroscler Thromb 2010; 17 (03) 285-294
    CrossrefPubMedGoogle Scholar
  • 19 Domei T, Yokoi H, Kuramitsu S. et al. Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J 2012; 76 (02) 423-429
    CrossrefPubMedGoogle Scholar
  • 20 Fukami A, Adachi H, Hirai Y. et al. Association of serum eicosapentaenoic acid to arachidonic acid ratio with microalbuminuria in a population of community-dwelling Japanese. Atherosclerosis 2015; 239 (02) 577-582
    CrossrefPubMedGoogle Scholar
  • 21 Ikeya Y, Fukuyama N, Kitajima W, Ogushi Y, Mori H. Comparison of eicosapentaenoic acid concentrations in plasma between patients with ischemic stroke and control subjects. Nutrition 2013; 29 (01) 127-131
    CrossrefPubMedGoogle Scholar
  • 22 Nagahara Y, Motoyama S, Sarai M. et al. Eicosapentaenoic acid to arachidonic acid (EPA/AA) ratio as an associated factor of high risk plaque on coronary computed tomography in patients without coronary artery disease. Atherosclerosis 2016; 250: 30-37
    CrossrefPubMedGoogle Scholar
  • 23 Ninomiya T, Nagata M, Hata J. et al. Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study. Atherosclerosis 2013; 231 (02) 261-267
    CrossrefPubMedGoogle Scholar
  • 24 Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96 (05) 1432-1437
    CrossrefPubMedGoogle Scholar
  • 25 O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK. Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340 (01) 14-22
    CrossrefPubMedGoogle Scholar